Abstract
Over the last decade, the class of the atypical antipsychotics has become the gold standard for the treatment of bipolar disorder (BD), at least for its manic/mixed phases. This phenomenon has different explanations: first, the number of compounds with formal approvals for BD is higher in comparison with other mood-stabilizers including lithium and anticonvulsants. Second, the sample size of randomized controlled trials assessing the efficacy and safety of different pharmacological treatments is usually larger for most recently approved compounds (i.e., atypical agents for the treatment of BD). If the role of atypical antipsychotics is well-established in the treatment of BD, doubts still persist about their optimal efficacy as monotherapy vs combination treatment with other mood-stabilizers, in particular. In addition, a possible superiority in terms of efficacy for polytherapy needs to be balanced in relation to tolerability issues. The present article was aimed to review the state of the art in the field reviewing the latest evidence arising from international guidelines recommendations and meta-analyses.
Keywords: Bipolar disorder, atypical antipsychotics, monotherapy, combination therapy
Current Psychopharmacology
Title:Use of Atypical Antipsychotics as Mono/Polytherapy with Mood Stabilizers for the Treatment of Bipolar Disorder. An Update
Volume: 2
Author(s): A. Carlo Altamura, Beatrice Benatti and Bernardo Dell’Osso
Affiliation:
Keywords: Bipolar disorder, atypical antipsychotics, monotherapy, combination therapy
Abstract: Over the last decade, the class of the atypical antipsychotics has become the gold standard for the treatment of bipolar disorder (BD), at least for its manic/mixed phases. This phenomenon has different explanations: first, the number of compounds with formal approvals for BD is higher in comparison with other mood-stabilizers including lithium and anticonvulsants. Second, the sample size of randomized controlled trials assessing the efficacy and safety of different pharmacological treatments is usually larger for most recently approved compounds (i.e., atypical agents for the treatment of BD). If the role of atypical antipsychotics is well-established in the treatment of BD, doubts still persist about their optimal efficacy as monotherapy vs combination treatment with other mood-stabilizers, in particular. In addition, a possible superiority in terms of efficacy for polytherapy needs to be balanced in relation to tolerability issues. The present article was aimed to review the state of the art in the field reviewing the latest evidence arising from international guidelines recommendations and meta-analyses.
Export Options
About this article
Cite this article as:
Carlo Altamura A., Benatti Beatrice and Dell’Osso Bernardo, Use of Atypical Antipsychotics as Mono/Polytherapy with Mood Stabilizers for the Treatment of Bipolar Disorder. An Update, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010047
DOI https://dx.doi.org/10.2174/2211556011302010047 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Virtual Screening Against Obesity
Current Medicinal Chemistry Commentary ( The Renin Angiotensin System in Alzheimers Disease - Do Updates Highlight a Clinical and Biological Dichotomy? )
Current Alzheimer Research Assessment of a Synthetic Steroid and Flutamide on Dopamine, GSH and H<sub>2</sub>O<sub>2</sub> Levels in Rat Brain in Presence of Fructose
Endocrine, Metabolic & Immune Disorders - Drug Targets The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets
CNS & Neurological Disorders - Drug Targets Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism N-Terminal Specific Fluorescence Labeling and its Use in Local Structure Analysis of Proteins (Invited Review)
Current Chemical Biology Intracellular Signaling by Phospholipase D as a Therapeutic Target
Current Pharmaceutical Biotechnology Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Cholecystokinin Antagonists A New Way to Improve the Analgesia from Old Analgesics?
Current Pharmaceutical Design Catecholaminergic Strategies for the Treatment of Major Depression
Current Drug Targets Phenyl Substituted Thiazole Linked 1, 2, 4-triazole Derivatives: Synthesis and Their Biological Evaluation
Letters in Organic Chemistry Advanced Membrane Systems for Tissue Engineering
Current Organic Chemistry